Nuvalent, Inc. (NUVL)Healthcare | Biotechnology | Cambridge, United States | NasdaqGS
107.61 USD
+3.75
(3.611%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 109.74 +2.13 (1.979%) ⇧ (April 17, 2026, 7:12 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 3:46 p.m. EDT
Nuvalent (NUVL) is currently in a volatile phase, with mixed signals from the options market and recent news. The stock has shown some upward momentum in the last few weeks, but fundamentals are weak with negative earnings and a high overall risk. The recent insider selling and public offering might indicate uncertainty about the company's future. While the options market suggests some bullish sentiment for the short term, the long-term fundamentals are concerning, making it a risky proposition for long-term investors. Given the lack of dividends and weak earnings, it's not a strong candidate for dividend-focused investors. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.042378 |
| AutoETS | 0.044246 |
| AutoARIMA | 0.047477 |
| AutoTheta | 0.048141 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 58% |
| H-stat | 2.21 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.263 |
| Excess Kurtosis | -0.62 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 8,459,975,168 |
| Forward P/E | -26.67 |
| Beta | 1.31 |
| Website | https://nuvalent.com |
As of April 11, 2026, 3:46 p.m. EDT: Options activity shows a mixed sentiment. For near-term expirations (April 17), there is significant OTM put activity, indicating some bearish sentiment, while calls show moderate positioning. For July 17, there is a concentration of OTM put and call positions, suggesting speculative activity around the stock's current price. Further out, the October 16 and January 15 expirations show low volume and limited positioning, indicating less activity. The high IV for puts in July suggests increased uncertainty or fear, while the ATM call activity may indicate potential for upward movement.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.53838456 |
| Address1 | One Broadway |
| Address2 | 14th Floor |
| All Time High | 113.51 |
| All Time Low | 7.09 |
| Ask | 107.9 |
| Ask Size | 1 |
| Audit Risk | 5 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 531,460 |
| Average Daily Volume3 Month | 549,335 |
| Average Volume | 549,335 |
| Average Volume10Days | 531,460 |
| Beta | 1.308 |
| Bid | 107.33 |
| Bid Size | 1 |
| Board Risk | 3 |
| Book Value | 15.955 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 107.61 |
| Current Ratio | 15.273 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 108.825 |
| Day Low | 104.54 |
| Display Name | Nuvalent |
| Earnings Timestamp | 1,772,112,600 |
| Earnings Timestamp End | 1,778,157,000 |
| Earnings Timestamp Start | 1,778,157,000 |
| Ebitda Margins | 0.0 |
| Enterprise Value | 7,088,023,552 |
| Eps Current Year | -5.50092 |
| Eps Forward | -4.03541 |
| Eps Trailing Twelve Months | -5.85 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 101.4643 |
| Fifty Day Average Change | 6.1456985 |
| Fifty Day Average Change Percent | 0.060570057 |
| Fifty Two Week Change Percent | 53.838455 |
| Fifty Two Week High | 113.015 |
| Fifty Two Week High Change | -5.404999 |
| Fifty Two Week High Change Percent | -0.0478255 |
| Fifty Two Week Low | 63.555 |
| Fifty Two Week Low Change | 44.055 |
| Fifty Two Week Low Change Percent | 0.69317913 |
| Fifty Two Week Range | 63.555 - 113.015 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,627,565,400,000 |
| Float Shares | 48,676,502 |
| Forward Eps | -4.03541 |
| Forward P E | -26.666435 |
| Free Cashflow | -141,616,880 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 228 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.027490001 |
| Held Percent Institutions | 1.1143 |
| Implied Shares Outstanding | 78,617,001 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-07-29 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; Neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts. |
| Long Name | Nuvalent, Inc. |
| Market | us_market |
| Market Cap | 8,459,975,168 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_702442629 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -425,376,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 8,467,837,177 |
| Number Of Analyst Opinions | 18 |
| Open | 105.89 |
| Operating Cashflow | -275,208,992 |
| Operating Margins | 0.0 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 857-357-7000 |
| Post Market Change | 2.1299973 |
| Post Market Change Percent | 1.9793674 |
| Post Market Price | 109.74 |
| Post Market Time | 1,776,467,561 |
| Previous Close | 103.86 |
| Price Eps Current Year | -19.562183 |
| Price Hint | 2 |
| Price To Book | 6.744594 |
| Profit Margins | 0.0 |
| Quick Ratio | 15.048 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.21053 |
| Region | US |
| Regular Market Change | 3.75 |
| Regular Market Change Percent | 3.61063 |
| Regular Market Day High | 108.825 |
| Regular Market Day Low | 104.54 |
| Regular Market Day Range | 104.54 - 108.825 |
| Regular Market Open | 105.89 |
| Regular Market Previous Close | 103.86 |
| Regular Market Price | 107.61 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 594,437 |
| Return On Assets | -0.20274 |
| Return On Equity | -0.367 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 10 |
| Shares Outstanding | 73,181,747 |
| Shares Percent Shares Out | 0.0633 |
| Shares Short | 4,976,718 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 5,538,341 |
| Short Name | Nuvalent, Inc. |
| Short Percent Of Float | 0.13260001 |
| Short Ratio | 8.8 |
| Source Interval | 15 |
| State | MA |
| Symbol | NUVL |
| Target High Price | 165.0 |
| Target Low Price | 116.0 |
| Target Mean Price | 142.38889 |
| Target Median Price | 140.0 |
| Total Cash | 1,371,952,000 |
| Total Cash Per Share | 17.451 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -5.85 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 93.81818 |
| Two Hundred Day Average Change | 13.791824 |
| Two Hundred Day Average Change Percent | 0.14700589 |
| Type Disp | Equity |
| Volume | 594,437 |
| Website | https://nuvalent.com |
| Zip | 2,142 |